Author:
Kim Ha-Neui,Ponte Filipa,Nookaew Intawat,Ucer Ozgurel Serra,Marques-Carvalho Adriana,Iyer Srividhya,Warren Aaron,Aykin-Burns Nukhet,Krager Kimberly,Sardao Vilma A.,Han Li,de Cabo Rafael,Zhao Haibo,Jilka Robert L.,Manolagas Stavros C.,Almeida Maria
Abstract
AbstractLoss of estrogens at menopause is a major cause of osteoporosis and increased fracture risk. Estrogens protect against bone loss by decreasing osteoclast number through direct actions on cells of the myeloid lineage. Here, we investigated the molecular mechanism of this effect. We report that 17β-estradiol (E2) decreased osteoclast number by promoting the apoptosis of early osteoclast progenitors, but not mature osteoclasts. This effect was abrogated in cells lacking Bak/Bax—two pro-apoptotic members of the Bcl-2 family of proteins required for mitochondrial apoptotic death. FasL has been previously implicated in the pro-apoptotic actions of E2. However, we show herein that FasL-deficient mice lose bone mass following ovariectomy indistinguishably from FasL-intact controls, indicating that FasL is not a major contributor to the anti-osteoclastogenic actions of estrogens. Instead, using microarray analysis we have elucidated that ERα-mediated estrogen signaling in osteoclast progenitors decreases “oxidative phosphorylation” and the expression of mitochondria complex I genes. Additionally, E2 decreased the activity of complex I and oxygen consumption rate. Similar to E2, the complex I inhibitor Rotenone decreased osteoclastogenesis by promoting osteoclast progenitor apoptosis via Bak/Bax. These findings demonstrate that estrogens decrease osteoclast number by attenuating respiration, and thereby, promoting mitochondrial apoptotic death of early osteoclast progenitors.
Funder
National Institutes of Health
University of Arkansas for Medical Sciences
U.S. Department of Veterans Affairs
National Institute on Aging
Publisher
Springer Science and Business Media LLC
Reference84 articles.
1. Manolagas, S. C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21, 115–137 (2000).
2. Almeida, M. et al. Estrogens and androgens in skeletal physiology and pathophysiology. Physiol. Rev. 97, 135–187. https://doi.org/10.1152/physrev.00033.2015 (2017).
3. Manolagas, S. C. Steroids and osteoporosis: the quest for mechanisms. J. Clin. Invest. 123, 1919–1921. https://doi.org/10.1172/JCI68062 (2013).
4. Hughes, D. E. et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-b. Nat. Med. 2, 1132–1136 (1996).
5. Manolagas, S. C., O’Brien, C. A. & Almeida, M. The role of estrogen and androgen receptors in bone health and disease. Nat. Rev. Endocrinol. 9, 699–712. https://doi.org/10.1038/nrendo.2013.179 (2013).
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献